// App-Quantinova.ai

3236 : Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Researchers

Presenter

  • Michael O'Dwyer

Principal Investigators

  • Andrew Spencer

  • Shaji K. Kumar

  • Rakesh Popat

  • Philippe Moreau

  • Monique Dail

  • Muhammad Jalaluddin

  • Xiaoqing Yang

  • Xin Lu

  • Zheng Zha

  • Fengjiao Dunbar

  • Deeksha Vishwamitra

  • Christine Mantis

  • Amal Melhem-Bertrandt

  • Jeremy A. Ross

  • Simon J Harrison

Medical Centers

  • The National University of Ireland, Galway, Ireland

  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Department of Medical Oncology, University College London Hospital, London, United Kingdom

  • Department of Hematology, Grenoble University Hospital, Grenoble, France

  • Genentech, Inc., South San Francisico, CA

  • AbbVie, Inc., North Chicago, IL

  • Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

Locations

  • Ireland

  • Australia

  • United States

  • United Kingdom

  • France

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • B-cell lymphoma 2

  • Granulin precursor

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bortezomib

  • Venetoclax

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02755597

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved